• Jaguar Health unit Napo signed a new manufacturing and supply agreement with Alivus Life Sciences to produce crofelemer for Mytesi and other products.
• Contract runs through March 31, 2029, with optional renewals of at least two years by mutual agreement.
• Napo committed to minimum crofelemer purchase volumes, pro-rated for the partial financial year; it may owe a shortfall payment.
• Either party can terminate with 12 months’ notice; Napo can exit sooner for regulatory withdrawal or chronic supply failures.
• Rights and obligations shift to Woodward Specialty if an insolvency event occurs under a separate January 2026 license arrangement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-303190), on July 14, 2026, and is solely responsible for the information contained therein.